Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Rituximab 3Brentuximab Vedotin 2venetoclax 1veltuzumab 1pirtobrutinib 1ontuxizumab 1iratumumab 1exatecan 1durvalumab 1Zidovudine 1Vincristine 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisone 1Prednisolone 1Oxaliplatin 1Mitoxantrone 1Mannose-Binding Lectin 1Lenalidomide 1Gemcitabine 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1Antibodies, Monoclonal 1Adrenal Cortex Hormones 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Dendritic Cell Sarcoma, Interdigitating × Gemcitabine × Clear all
NCT07570823 2026-05-06

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sinocelltech Ltd.

Phase 3 Not yet recruiting
101 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡